Research Compounds

ADAMAX vs. Semax vs. Selank: What the Research Shows

Research comparison

Three research names.
Different evidence profiles.

ADAMAX

Compound-specific evidence not identified in this review.

Semax

Neurotrophin-related experimental findings.

Selank

Neurotransmission-related experimental findings.

Evidence overview, not a ranking of efficacy or safety.

ADAMAX, Semax and Selank are distinct research materials, and the evidence behind their names is not interchangeable. Semax and Selank appear in original experimental publications. For ADAMAX, the sources searched for this article did not identify a compound-specific peer-reviewed experimental study. That difference matters when comparing mechanisms, planning a laboratory project or reviewing a supplier listing.

This ADAMAX vs. Semax vs. Selank comparison separates published observations from assumptions. Researchers can also review the corresponding VialBench listings and batch documentation below.

For laboratory research and identification only. VialBench products are not intended for human or animal use, dosing, injection or ingestion. This article is not medical advice. VialBench sells the materials linked below; the cited studies do not evaluate or endorse VialBench products.

ADAMAX vs. Semax vs. Selank at a glance

Research namePublished research discussed hereMain limitationVB listing
ADAMAXNo compound-specific primary experimental paper identified in this article’s searchIdentity and claimed advantages require independent documentation; Semax findings cannot be assigned to ADAMAXVB-ADAMAX
SemaxRat neurotrophin studies and a small human functional-connectivity studyMolecular and imaging findings do not establish a treatment outcomeVB-Semax
SelankNeurotransmission-related gene-expression studies and a small human functional-connectivity studyResponses depend on the model, endpoint and experimental conditionsVB-Selank

What is ADAMAX? Start with identity and evidence

ADAMAX is the research name used on the VB-ADAMAX listing. A catalog name alone does not establish an exact molecular structure, mechanism or equivalence to another peptide. Researchers should request the sequence, terminal modifications and analytical identity documentation needed for their specific experiment.

In targeted web searches, including searches restricted to PubMed, for ADAMAX with peptide- and Semax-related terms, we did not identify a compound-specific peer-reviewed experimental publication for this comparison. This is a bounded literature search, not proof that no report exists anywhere.

Claims that ADAMAX is stronger, longer lasting or better at reaching the brain require direct measurements on a clearly identified material. Neither a structural analogy nor a supplier description establishes those claims. Published Semax findings should therefore remain labeled as Semax findings.

Semax research: neurotrophin findings in experimental models

Semax is an ACTH-fragment-related synthetic peptide. In a rat hippocampus study, Dolotov and colleagues reported changes in BDNF-related measures, including BDNF expression and TrkB signaling, alongside a behavioral task. These observations support further work on neurotrophin-related pathways in that model. They do not demonstrate that a research vial improves human cognition. [1]

A separate rat study examined NGF and BDNF gene expression across the hippocampus, frontal cortex and retina over time. The direction of the response differed with tissue and sampling time. Describing Semax simply as something that “increases BDNF” loses that experimental context. [2]

For a laboratory comparison, define the tissue or cell model, endpoint, sampling window and controls before choosing a material. A change in gene expression, protein abundance or receptor phosphorylation answers a different question from a clinical outcome.

Selank research: neurotransmission-related endpoints

Selank is a synthetic tuftsin-related peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. A 2016 rat study assessed gene-expression responses in the frontal cortex and found changes among genes associated with neurotransmission, including GABAergic processes. Gene-expression responses can suggest pathways for investigation; they do not by themselves establish direct binding to a receptor or a treatment effect in people. [3]

A subsequent experiment used IMR-32 human neuroblastoma cells. Under its tested conditions, Selank alone did not change the measured gene-expression endpoints, while responses differed in combination conditions. A cell-line experiment and a rat brain experiment are different systems. Their results should be interpreted with those differences visible. [4]

What does the human Semax vs. Selank study show?

A 2020 publication studied resting-state functional connectivity in 52 healthy participants receiving Semax, Selank or placebo. The authors reported shared and distinct short-term connectivity findings involving the right amygdala and temporal regions. This was an imaging study, not a demonstration of long-term clinical benefit, and ADAMAX was not included. It cannot establish a three-way ranking for efficacy or safety. [5]

Shop ADAMAX, Semax and Selank research listings

The following product pages were checked during preparation of this article. Each displayed a 10 mg option, in-stock status and an available purchase control. Availability can change; confirm the selected option and current details on the product page.

VB-ADAMAX research product

VB-ADAMAX

ADAMAX · 10 mg option
Review the specification and batch documentation. Semax publications do not validate ADAMAX performance.

View VB-ADAMAX & purchase
VB-Semax research product

VB-Semax

Semax · 10 mg option
Review the individual listing and match its documentation to the material required by your laboratory protocol.

View VB-Semax & purchase
VB-Selank research product

VB-Selank

Selank · 10 mg option
Review the separate Selank listing. The same vial quantity does not make Selank and Semax equivalent materials.

View VB-Selank & purchase

For laboratory research and identification only. Check current availability, selected options and lot documentation on each product page. Not for human or animal use.

Check the material before comparing results

  • Confirm identity: obtain the sequence, modifications and relevant analytical identity results. Similar names are not proof of equivalence.
  • Match the lot: compare the supplied batch with the corresponding certificate of analysis. A report for another batch is not documentation for the vial in hand.
  • Separate purity from quantity: chromatographic purity and peptide content describe different measurements. Review which methods and results the report actually provides.
  • Keep the study conditions visible: record the experimental system, controls and endpoint. Published findings do not certify a supplier’s lot or establish suitability for every protocol.

Frequently asked research questions

Are ADAMAX, Semax and Selank the same peptide?

No. Treat each as a separate material and verify its identity documentation. Selank and Semax have different research histories; the ADAMAX name does not make Semax results transferable.

Is ADAMAX stronger than Semax?

The evidence reviewed here does not establish that comparison. A potency claim needs a defined assay, verified materials and direct comparative data.

Does this article recommend combining them?

No. It compares research evidence and catalog listings. It provides no dosing, administration or combination-use instructions.

Where can researchers find the corresponding VB products?

Use the individual VB-ADAMAX, VB-Semax and VB-Selank pages for current options and availability. Review batch documentation before purchasing for an appropriate laboratory project.

Primary research references

  1. Dolotov et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.
  2. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action.
  3. Volkova et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.
  4. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells (2017).
  5. Panikratova et al. (2020). Functional Connectomic Approach to Studying Selank and Semax Effects.

Literature and product-page review: November 17, 2026. This comparison is educational and is not a systematic review. All linked VB products are for laboratory research and identification only, not for human or animal use.